OLYMPUS CORPORATION (7733) Stock Price

Olympus is a company primarily engaged in the manufacturing and sale of endoscopes and therapeutic devices. In the endoscope business, it provides gastrointestinal endoscopes, surgical endoscopes, and medical services. Key affiliated companies in this field include Olympus Medical Systems and Olympus Marketing.

In the therapeutic devices business, the company handles gastrointestinal procedure instruments, urology products, respiratory products, energy devices, otolaryngology products, and gynecology products. These products are provided through Olympus Medical Systems and Olympus Marketing, which are consolidated subsidiaries of Olympus.

Olympus also operates through holding company activities and financial investments. This involves subsidiaries such as Olympus Corporation of the Americas and Olympus Europa Holding SE. These activities support the diversification and growth of Olympus's business operations.

Olympus is committed to its management philosophy of "realizing the health, safety, and peace of mind of people worldwide, as well as enriching their lives." The company aims to contribute to society through innovative products and services. Since April 2023, Olympus has strengthened its leadership in the healthcare industry by adopting three core principles: "patient safety and sustainability," "innovation for growth," and "productivity improvement."

The company's growth strategy, named "Shift to Grow," aims to achieve both growth and profitability. Specifically, Olympus is improving patient experience value and treatment outcomes through business expansion and global deployment, strategic M&A, care pathway enhancement, and the development of an intelligent endoscopy medical ecosystem.

Olympus focuses on three clinical areas: gastroenterology, urology, and respiratory medicine, providing advanced imaging, precise treatment, and high-value solutions. The company is expanding sales of its gastrointestinal endoscopy system "EVIS X1" and single-use endoscopes, while also considering the establishment of local production facilities in the Chinese market.

Through strategic M&A, Olympus is strengthening its product portfolio in existing disease areas and related fields, while driving transformation in clinical and therapeutic workflows. This approach aims to improve patient treatment outcomes and expand the business geographically.

In its intelligent endoscopy medical ecosystem, Olympus seeks to enhance the experience of healthcare providers and patients by leveraging AI and data insights. The company plans to launch the "OLYSENSE" brand in 2026 and deploy CAD/AI products in Europe and North America.

Olympus is advancing the "Elevate" transformation project to enhance quality assurance and regulatory compliance. The initiative focuses on improving product lifecycle management and digitalizing business processes. Through these efforts, Olympus aims to realize future innovation, growth, and improved profitability.